- media@moneyinfocus.news
Advanced nuclear technology company Oklo continued expanding its engineering and manufacturing capabilities through a series of acquisitions while increasing investment in its commercialization strategy, underscoring its long-term focus on next-generation nuclear energy despite remaining in a pre-revenue stage.
The company completed the acquisitions of Creative Engineers and ARMEC, strengthening its engineering, manufacturing and deployment capabilities for advanced nuclear reactors.
Oklo also acquired Atomic Alchemy in a transaction valued at $25 million, broadening its presence beyond power generation into the medical isotope market while enhancing capabilities in nuclear fuel recycling.
The acquisition of Atomic Alchemy represents a strategic diversification into medical isotopes, which are widely used in diagnostic imaging, cancer treatment and scientific research.
The transaction also complements Oklo’s broader strategy of developing an integrated nuclear fuel cycle designed to support advanced reactor operations and improve fuel sustainability.
The company has positioned fuel recycling as a key component of its long-term business model alongside advanced reactor deployment.
As Oklo advances toward commercialization, operating expenses have continued to increase.
During the first quarter of 2026, the company reported a net loss of $33.1 million, primarily reflecting an operating loss of $51.2 million.
Total operating expenses rose significantly, increasing from approximately $52 million to $139 million during 2025 as the company expanded engineering capabilities, research activities and commercialization efforts.
The financial results remain consistent with Oklo’s development-stage profile, where investment in technology, licensing and manufacturing infrastructure continues to outpace revenue generation.
To support future growth, Oklo raised more than $1 billion through an equity offering completed in early 2026.
Following the transaction, the company reported approximately $2.5 billion in liquidity, providing additional financial flexibility as it continues reactor development, licensing activities and strategic acquisitions.
Oklo reported no revenue during the fourth quarter of 2025, alongside an operating loss of $57.1 million, highlighting that the company has not yet entered large-scale commercial operations.
Despite its current pre-revenue status, analysts expect revenue to begin increasing as commercialization progresses.
Consensus estimates project first-quarter 2026 revenue of approximately $239.9 million, compared with $224.1 million in the same period a year earlier.
The company continues to focus on obtaining regulatory approvals, expanding engineering capabilities and advancing customer deployments as the advanced nuclear sector attracts growing investor attention amid rising global demand for reliable, low-carbon energy sources.
